文献速递关节外科运动医学

无柄解剖型全肩关节置换术中聚乙烯盂组件在原发性与继发性骨关节炎中的高失败率

High Failure Rates of Polyethylene Glenoid Components in Stemless Anatomic Total Shoulder Arthroplasty for Primary and Secondary OA.
PubMed 文献 · J Bone Joint Surg Am · 2025-06-25

研究纳入211例接受无柄解剖型全肩关节置换术并使用Eclipse肱骨组件与骨水泥固定带桩全聚乙烯盂组件的患者,197例完成评估。中位术后72个月总体翻修率为51%,盂组件松动占翻修原因的85%。原发性和继发性骨关节炎患者的中位假体生存期分别为95个月和71个月,差异有统计学意义。

要点

  • 中位随访72个月,总体翻修率51%,盂组件松动占翻修原因的85%。
  • 原发性骨关节炎中位假体生存期95个月,继发性骨关节炎71个月,差异有统计学意义。
  • 继发性骨关节炎、盂内侧骨水泥渗透和肱骨组件前方悬突与翻修风险增加相关。

核心结论

  • 在接受Eclipse无柄解剖型全肩关节置换术并使用骨水泥固定带桩全聚乙烯盂组件的原发性和继发性骨关节炎患者中,盂组件松动是翻修的主要原因且发生率较高。
  • 该结果强调需要仔细考虑植入物设计、患者选择标准以及植入物定位和骨水泥技术以优化假体生存。

研究设计与样本

  • 研究类型为治疗性III级证据。
  • 在本地注册库中前瞻性记录数据的211例初次无柄解剖型全肩关节置换术患者中,197例完成评估,按骨关节炎病理分组:原发性骨关节炎153例,继发性骨关节炎44例。
  • 术前记录两组人口学和功能数据(如年龄、性别、肩关节功能)及骨关节炎病因,并进行组间并发症和植入物翻修的对比分析。
  • 评估多种影像学参数(如盂形态、临界肩角、外侧肩峰指数、植入物尺寸[肱骨组件悬突]、肱骨和盂组件的径向匹配、盂肱距离、盂内侧骨水泥渗透)以探索其与翻修的潜在关联,并基于临床相关性将部分参数纳入多变量Cox模型。

主要发现

  • 中位术后72个月,总体翻修率为51%。
  • 翻修原因包括盂组件松动(85%)、假体周围肱骨骨折(9%)、早期肩袖失效(3%)和低度感染(3%)。
  • 原发性骨关节炎患者的中位假体生存期为95个月(95%CI:84至108),继发性骨关节炎患者为71个月(95%CI:60至88),差异有统计学意义(p=0.027)。
  • 女性患者的翻修时间显著短于男性患者(p=0.016)。
  • 按骨关节炎病理分组的并发症或翻修率无显著差异;继发性骨关节炎、盂内侧骨水泥渗透和肱骨组件前方悬突与翻修风险增加相关。

关键数值与推荐

  • 总体翻修率51%,中位术后随访72个月。
  • 翻修原因:盂组件松动85%,假体周围肱骨骨折9%,早期肩袖失效3%,低度感染3%。
  • 原发性骨关节炎中位假体生存期95个月(95%CI:84至108) vs 继发性骨关节炎71个月(95%CI:60至88),p=0.027。
  • 女性翻修时间显著短于男性(p=0.016)。
  • 继发性骨关节炎、盂内侧骨水泥渗透和肱骨组件前方悬突与翻修风险增加相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glenoid component loosening remains a challenge in anatomic total shoulder arthroplasty (aTSA). The aims of this study were to evaluate complications, implant survival, and revision rates in patients with primary and secondary osteoarthritis (OA) undergoing stemless aTSA using the Arthrex Eclipse humeral implant with a cemented pegged all-polyethylene glenoid component and to identify risk factors leading to revision. METHODS: Of 211 patients who underwent primary stemless aTSA (using the Eclipse humeral component with a cemented pegged all-polyethylene glenoid) with prospectively documented data in a local registry, 197 were evaluated, grouped by OA pathology (primary OA, 153 patients; secondary OA, 44 patients). Demographic and functional data (e.g., age, sex, shoulder function) and the cause of OA were documented preoperatively in both groups. Comparative analyses were conducted to assess complications and implant revisions between the study groups. In addition, various radiographic parameters (e.g., glenoid morphology, critical shoulder angle, lateral acromion index, implant sizing [humeral component overhang], radial matching of the humeral and glenoid components, glenohumeral distance, and medial glenoid cement penetration) were evaluated to explore their potential association with revision. A subset of these parameters was subsequently included in the multivariable Cox model on the basis of clinical relevance. RESULTS: After a median postoperative period of 72 months, the overall revision rate was 51%. The reasons for revision were glenoid component loosening (85%), periprosthetic humeral fracture (9%), early rotator cuff failure (3%), and low-grade infection (3%). The median implant survival in patients with primary OA (95 months; 95% confidence interval [CI]: 84 to 108) was significantly longer than that in patients with secondary OA (71 months; 95% CI: 60 to 88; p = 0.027). Female patients had a significantly shorter time to revision than male patients (p = 0.016). There were no significant differences in complications or revision rates by OA pathology. Secondary OA, the presence of medial glenoid cement penetration, and an anterior overhang of the humeral component were associated with an increased risk of revision. CONCLUSIONS: Our findings indicate a high rate of glenoid component loosening as the primary cause of revision in patients with primary and secondary OA undergoing stemless aTSA with the Eclipse and a cemented pegged all-polyethylene glenoid component. This outcome emphasizes the need for careful consideration of implant design, patient selection criteria, and implant positioning and cementation in order to optimize implant survival. LEVEL OF EVIDENCE: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Kraus M, Lazaridou A, Warnhoff M, et al. High Failure Rates of Polyethylene Glenoid Components in Stemless Anatomic Total Shoulder Arthroplasty for Primary and Secondary OA. J Bone Joint Surg Am. 2025. PMID: 40560961. doi:10.2106/JBJS.24.01126

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。